There is some debate on whether the Indian regulatory agency ought to have banned anti-diabetes drug pioglitazone given the large diabetic population in India. The decision to ban is a correct and proactive step considering the harm that it may cause in patients who have been taking the drug for over two years. Since hardly … Continue reading Guest column : In defence of India’s pioglitazone ban
Apothecurry 